My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 200

    1.

    Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy.

    Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC; HOPE Study; MICRO-HOPE Study.

    Diabetes Care. 2002 Nov;25(11):1919-27.PMID: 12401733 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

    [No authors listed]

    Lancet. 2000 Jan 22;355(9200):253-9. Erratum in: Lancet 2000 Sep 2;356(9232):860. PMID: 10675071 [PubMed - indexed for MEDLINE]Related articles

    3.

    Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

    Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P.

    N Engl J Med. 2000 Jan 20;342(3):154-60.PMID: 10639540 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study.

    Mann JF, Lonn EM, Yi Q, Gerstein HC, Hoogwerf BJ, Pogue J, Bosch J, Dagenais GR, Yusuf S; HOPE Investigators.

    Kidney Int. 2004 Apr;65(4):1375-80.PMID: 15086477 [PubMed - indexed for MEDLINE]Related articles

    5.

    Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.

    Gerstein HC, Bosch J, Pogue J, Taylor DW, Zinman B, Yusuf S.

    Diabetes Care. 1996 Nov;19(11):1225-8.PMID: 8908384 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.

    Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR; HOPE and HOPE-TOO Trial Investigators.

    JAMA. 2005 Mar 16;293(11):1338-47.PMID: 15769967 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis.

    Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, Yusuf S; HOPE investigators.

    Diabetologia. 2005 Sep;48(9):1749-55. Epub 2005 Jul 30.PMID: 16059716 [PubMed - indexed for MEDLINE]Related articles

    8.

    Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.

    Gerstein HC.

    Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S82-5. Review.PMID: 12324991 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effect of long-term therapy with ramipril in high-risk women.

    Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, Bosch J, Suhan P, Micks M, Probstfield J, Bernstein V, Yusuf S; HOPE Investigators. Heart Outcomes Prevention Evaluation.

    J Am Coll Cardiol. 2002 Aug 21;40(4):693-702.PMID: 12204499 [PubMed - indexed for MEDLINE]Related articles

    10.

    Diabetes and the HOPE study: implications for macrovascular and microvascular disease.

    Gerstein HC.

    Int J Clin Pract Suppl. 2001 Jan;(117):8-12.PMID: 11715357 [PubMed - indexed for MEDLINE]Related articles

    11.

    Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.

    Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group.

    Diabetes Care. 2003 Dec;26(12):3264-72.PMID: 14633812 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.

    Sumner G, Salehian O, Yi Q, Healey J, Mathew J, Al-Merri K, Al-Nemer K, Mann JF, Dagenais G, Lonn E; HOPE Investigators.

    J Cardiovasc Electrophysiol. 2009 Jul;20(7):781-7. Epub 2009 Feb 27.PMID: 19298567 [PubMed - indexed for MEDLINE]Related articles

    13.

    Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.

    N Engl J Med. 2000 Jan 20;342(3):145-53. Erratum in: 2000 May 4;342(18):1376. N Engl J Med 2000 Mar 9;342(10):748. PMID: 10639539 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.

    Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE.

    JAMA. 2005 Jul 6;294(1):56-65.PMID: 15998891 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.

    Dagenais GR, Yi Q, Lonn E, Sleight P, Ostergren J, Yusuf S; HOPE Trial Investigators.

    Eur J Cardiovasc Prev Rehabil. 2005 Feb;12(1):75-81.PMID: 15703510 [PubMed - indexed for MEDLINE]Related articles

    16.

    The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.

    [No authors listed]

    Can J Cardiol. 1996 Feb;12(2):127-37.PMID: 8605634 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.

    Lonn E, Held C, Arnold JM, Probstfield J, McQueen M, Micks M, Pogue J, Sheridan P, Bosch J, Genest J, Yusuf S; HOPE-2 Investigators.

    Can J Cardiol. 2006 Jan;22(1):47-53.PMID: 16450017 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.

    Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A; LIPID Study Group.

    Diabetes Care. 2003 Oct;26(10):2713-21.PMID: 14514569 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.

    Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM.

    JAMA. 2008 Nov 12;300(18):2123-33. Epub 2008 Nov 9.PMID: 18997197 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

    Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group.

    Lancet. 2003 Jun 14;361(9374):2005-16.PMID: 12814710 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity